

2007

## Structural and functional characterisation of the extracellular chaperone clusterin

E. M. Stewart

*University of Wollongong*, [elises@uow.edu.au](mailto:elises@uow.edu.au)

Follow this and additional works at: <https://ro.uow.edu.au/theses>

### University of Wollongong

#### Copyright Warning

You may print or download ONE copy of this document for the purpose of your own research or study. The University does not authorise you to copy, communicate or otherwise make available electronically to any other person any copyright material contained on this site.

You are reminded of the following: This work is copyright. Apart from any use permitted under the Copyright Act 1968, no part of this work may be reproduced by any process, nor may any other exclusive right be exercised, without the permission of the author. Copyright owners are entitled to take legal action against persons who infringe their copyright. A reproduction of material that is protected by copyright may be a copyright infringement. A court may impose penalties and award damages in relation to offences and infringements relating to copyright material.

Higher penalties may apply, and higher damages may be awarded, for offences and infringements involving the conversion of material into digital or electronic form.

Unless otherwise indicated, the views expressed in this thesis are those of the author and do not necessarily represent the views of the University of Wollongong.

### Recommended Citation

Stewart, Elise M, Structural and functional characterisation of the extracellular chaperone clusterin, PhD thesis, School of Biological Sciences, University of Wollongong, 2007. <http://ro.uow.edu.au/theses/53>

Research Online is the open access institutional repository for the University of Wollongong. For further information contact the UOW Library: [research-pubs@uow.edu.au](mailto:research-pubs@uow.edu.au)

## **NOTE**

This online version of the thesis may have different page formatting and pagination from the paper copy held in the University of Wollongong Library.

## **UNIVERSITY OF WOLLONGONG**

### **COPYRIGHT WARNING**

You may print or download ONE copy of this document for the purpose of your own research or study. The University does not authorise you to copy, communicate or otherwise make available electronically to any other person any copyright material contained on this site. You are reminded of the following:

Copyright owners are entitled to take legal action against persons who infringe their copyright. A reproduction of material that is protected by copyright may be a copyright infringement. A court may impose penalties and award damages in relation to offences and infringements relating to copyright material. Higher penalties may apply, and higher damages may be awarded, for offences and infringements involving the conversion of material into digital or electronic form.

---


# **Structural and Functional Characterisation of the Extracellular Chaperone Clusterin**

By

**Elise Marie Stewart**  
Bachelor of Science (Honours) Advanced

A thesis submitted in fulfillment of the requirements for the degree of

**Doctor of Philosophy**



**School of Biological Sciences**

University of Wollongong  
Wollongong, Australia

December 2007

## **Declaration of Authenticity**

This thesis is submitted in accordance with the regulations of the University of Wollongong in fulfilment of the degree of Doctor of Philosophy. It does not include any material previously published by another person except where due reference is made in the text. The experimental work described in this thesis is original, and has not been submitted for a degree to any other university.

Elise Marie Stewart

---

## **Acknowledgements**

Thanks Mark for giving me the opportunity and support to get to this point. It has been a long and eventful road to this point so thanks for weathering the storm so to speak and getting me here in the end.

To all those members of the Wilson lab for sharing the journey and making it a fun time regardless of the results, particularly Amy, Rachel, Justin and Steve, as well as honorary members Christine and Kara.

To all the ladies who have also helped and encouraged me along the way, Christine, Kara, Gillian, Martina, Rachel, Amy, Fiona, Tam, Teresa.

To my parents for their unwavering support, I will forgive the despairing “when are you going to finish?” questions, I did finally make it to the end.

And to Jason, what can I say, it has been a tough few years but we have come through it. Thanks for doing the hard yards and being there for me and believing in me, I appreciate it more than you know.

Yipee!!

---

## Table of Contents

<b>Declaration of Authenticity</b> .....	<b>ii</b>
<b>Acknowledgements</b> .....	<b>iii</b>
<b>Table of Contents</b> .....	<b>iv</b>
<b>List of Tables</b> .....	<b>vii</b>
<b>List of Figures</b> .....	<b>viii</b>
<b>Abbreviations</b> .....	<b>xi</b>
<b>Publications and Conference Presentations</b> .....	<b>xiii</b>
<b>Abstract</b> .....	<b>xiv</b>
<b>Chapter 1: Introduction</b> .....	<b>2</b>
1.1. <i>Protein Structure and Folding</i> .....	2
1.2. <i>Intracellular Mechanisms to Control Protein Folding</i> .....	4
1.2.1. Lysosomes.....	6
1.2.2. Chaperones .....	6
1.2.3. The Ubiquitin-Proteasome System.....	7
1.2.4. Aggresomes.....	8
1.3. <i>Extracellular Mechanisms to Control Protein Folding</i> .....	9
1.3.1. Protein Conformational Diseases.....	9
1.3.1.1. Amyloid Diseases.....	10
1.3.1.2. Clusterin and Amyloid .....	15
1.3.2. Extracellular Chaperones.....	16
1.3.2.1. Clusterin .....	17
1.3.2.2. Haptoglobin .....	22
1.3.2.3. Serum Amyloid P Component (SAP).....	23
1.3.3. The Low-Density Lipoprotein (LDL) Receptor Superfamily.....	25
1.4. <i>Clusterin Structure and Chaperone Action</i> .....	29
1.5. <i>Objectives</i> .....	32
<b>Chapter 2: General Materials and Methods</b> .....	<b>34</b>
2.1. <i>DNA Based Methods</i> .....	34
2.1.1. DNA Concentration Determination .....	34
2.1.2. Agarose Gel Electrophoresis .....	34
2.2. <i>Protein Based Methods</i> .....	35
2.2.1. Determination of Protein Concentrations.....	35
2.2.2. Sodium Dodecyl Sulphate-Polyacrylamide Gel Electrophoresis.....	35
2.2.3. Immunoblotting .....	36
2.2.4. Purification of Clusterin from Human Serum .....	38
2.2.5. Production of Anti-Clusterin Antibody Column .....	39
2.2.6. Size Exclusion Chromatography (SEC).....	40
2.2.7. Chaperone Assays.....	41
2.2.8. Reduction and Alkylation of Proteins.....	42
2.3. <i>General Bacterial Methods</i> .....	42
2.3.1. Bacterial Culture .....	42

2.3.2. Electroporation of Bacteria .....	43
2.4. <i>General Tissue Culture Methods</i> .....	43
2.4.1. Tissue Culture.....	43
2.4.2. Cryogenic Storage of Cell Lines.....	44
2.4.3. IgG Depletion of Foetal Calf Serum .....	44
<b>Chapter 3: Generation of Clusterin Mutants for Structural and Functional Studies .....</b>	<b>46</b>
3.1. <i>Introduction</i> .....	46
3.2. <i>Methods</i> .....	48
3.2.1. Design of Clusterin Mutants .....	48
3.2.2. Gateway Cloning System.....	48
3.2.3. Sequencing of Mutant Plasmids.....	52
3.2.4. Transfection of Mammalian Cells .....	52
3.2.5. Confirmation of Clusterin Expressing Transfected CHO Cells.....	53
3.2.6. Cloning of Mutant Clusterin Expressing CHO Cells.....	54
3.2.7. Expression of Mutant Clusterin .....	56
3.2.8. Testing Purity and Solution Behaviour of Mutant Clusterin Molecules.....	58
3.3. <i>Results</i> .....	59
3.3.1. Design of Mutant Clusterin Sequences .....	59
3.3.2. Entry Clone Plasmids.....	60
3.3.3. Insertion of Coding Regions into Destination Plasmids .....	62
3.3.4. Sequencing.....	62
3.3.5. Testing of Initial Transfected Cell Lines for Mutant Clusterin Expression .....	68
3.3.6. Testing Reactivity of Individual Anti-Clusterin Monoclonal Antibodies with Mutant Clusterin Proteins.....	69
3.3.7. Testing for Stable Transfection of Mutant Cell Lines .....	71
3.3.8. Expression Screening of Primary and Secondary CHO Cell Clones .....	72
3.3.9. Testing for Secretion of Clusterin Mutant Proteins Lacking the Signal Peptide .....	73
3.3.10. Initial Testing of Purification of CHO Expressed Wild Type Clusterin .....	74
3.3.11. Rolling miniPERM vs Static Cultures .....	77
3.3.12. Further Testing of Expression Conditions .....	78
3.3.13. Mutant Clusterin Purification .....	81
3.3.14. Screening of Reactivity of the 41D Antibody with Clusterin Mutants in Native, Denatured and Reduced States .....	83
3.3.15. Size Exclusion Chromatography Comparing Purified Clusterin Mutants pH 5.5 and 7.4.....	84
3.4. <i>Discussion</i> .....	86
<b>Chapter 4: Effects of Enzymatic Deglycosylation on the Structure and Function of Clusterin .....</b>	<b>91</b>
4.1. <i>Introduction</i> .....	91
4.2. <i>Methods</i> .....	93
4.2.1. Enzymatic Deglycosylation of Clusterin.....	93
4.2.2. Mass Spectrometry (MS) .....	93
4.2.3. Circular Dichroism Spectrometry.....	94
4.2.4. Measurements of bisANS Fluorescence .....	94
4.2.5. Size Exclusion Chromatography .....	95
4.2.6. ELISA Analyses .....	95
4.2.6.1. Native Protein Ligands .....	96
4.2.6.2. Stressed Protein Ligands .....	96
4.2.7. Protein Precipitation Assays .....	97
4.2.8. Surface Plasmon Resonance (SPR) Analysis.....	97
4.2.9. Cell Culture and Flow Cytometry.....	98
4.3. <i>Results</i> .....	100
4.3.1. Enzymatic Deglycosylation of Human Clusterin .....	100
4.3.2. Mass Spectrometry .....	101

4.3.3. CD Analyses of WT and DG Clusterin .....	103
4.3.4. BisANS fluorescence .....	104
4.3.5. Size Exclusion Chromatography .....	106
4.3.6. Binding to Native and Stressed Protein Ligands .....	107
4.3.7. Surface Plasmon Resonance (SPR) Analysis of Clusterin Binding to Megalin.....	111
4.3.8. <i>In Vitro</i> Chaperone Assays .....	113
4.3.9. Binding to HepG2 Cells.....	114
4.4. <i>Discussion</i> .....	116
<b>Chapter 5: Examining the Structure and Function of Recombinant Domains of Clusterin .....</b>	<b>123</b>
5.1. <i>Introduction</i> .....	123
5.2. <i>Methods</i> .....	125
5.2.1. Sequence Analysis of Clusterin Domains using PONDR and ProtScale .....	125
5.2.2. Cloning of Sequences Encoding Clusterin Domains into Expression Vectors .....	125
5.2.3. Sequencing of Plasmid Constructs .....	127
5.2.4. Protein Expression Conditions .....	131
5.2.5. Protein Purification Procedure .....	132
5.2.5.1. $\alpha$ N Domain .....	132
5.2.5.2. $\beta$ C Domain .....	133
5.2.6. Reduction and Alkylation of Recombinant Domains.....	134
5.2.7. Determination of Protein Concentration .....	135
5.2.8. Circular Dichroism (CD) Studies .....	135
5.2.9. Measurements of bisANS Fluorescence .....	136
5.2.10. Chaperone Assays.....	137
5.2.11. Surface Plasmon Resonance (SPR) Analysis .....	137
5.2.12. Biotinylation of Recombinant Domains.....	138
5.2.13. ELISA Analyses .....	139
5.2.13.1. Native Protein Ligand .....	139
5.2.13.2. Stressed Protein Ligand .....	140
5.2.13.3. Interaction Between Domains.....	140
5.3. <i>Results</i> .....	141
5.3.1. Sequence Analysis of Four Domains of Clusterin .....	141
5.3.2. PCR Amplification of DNA Encoding Clusterin Domains.....	142
5.3.3. Cloning of PCR Products into Expression Vectors .....	143
5.3.4. Sequencing of Plasmid Constructs Encoding Clusterin Domains.....	145
5.3.5. Verification of Construct Expression .....	148
5.3.6. Circular Dichroism (CD) Studies of Clusterin Domains .....	152
5.3.7. BisANS Binding Studies.....	155
5.3.8. Chaperone Activity of Clusterin Domains.....	157
5.3.9. Surface Plasmon Resonance (SPR) Measurements of Binding to LRP.....	160
5.3.10. Binding to Native and Stressed Protein Ligands .....	162
5.3.11. $\alpha$ N- $\beta$ C Interaction.....	165
5.4. <i>Discussion</i> .....	166
<b>Chapter 6: Conclusions and Future Directions.....</b>	<b>172</b>
<b>Reference List .....</b>	<b>177</b>



---

## List of Tables

Table 1.1:	Amyloid diseases and the protein involved in the pathology of the disease...	12
Table 1.2:	Known clusterin ligands.....	18
Table 2.1:	Reagents used for the Bichinchoninic Acid protein determination assay .....	35
Table 3.1:	Components of the LR reaction .....	51
Table 3.2:	Sequencing primers used to sequence each of the ten mutant clusterin plasmids from the parent vector pcDNA3.2-DEST.....	52
Table 3.3:	Ten clusterin mutants designed based on predicted structural interruptions to the predicted secondary structure of the clusterin molecule. ....	59
Table 4.1:	Predicted secondary structural elements as based on CD data.....	103
Table 4.2:	BisANS fluorescence results. ....	105
Table 4.3:	Analysis of the binding of WT and DG clusterin to native and stressed proteins in ELISA.....	111
Table 4.4:	Estimated kinetic constants for the binding of WT and DG clusterin to megalin.....	113
Table 5.1:	Sequences encoding the four clusterin domains to be expressed. ....	128
Table 5.2:	Primer pairs used to amplify DNA encoding domains of clusterin for expression as six-histidine tagged proteins. ....	129
Table 5.3:	Cycling conditions used for PCR amplification of DNA fragments for subsequent cloning reactions .....	130
Table 5.4:	Sequencing primers used to sequence inserts in plasmids pET 101 and pET 151, and pQE60. ....	130
Table 5.5:	Cycling conditions for the sequencing reaction cycle performed for the confirmation of cloned clusterin fragments in vectors. ....	130
Table 5.6:	Physical parameters for recombinant clusterin domains obtained from the ExPASy proteomics server (ProtParam programme).....	135
Table 5.7:	Results obtained from the Protein Express optimisation of expression for the nominated constructs based on coomassie stained SDS-PAGE. ....	149
Table 5.8:	Expression strain and conditions to obtain optimal expression of each six-histidine tagged clusterin construct.....	149
Table 5.9:	Estimated percentage of $\alpha$ -helical structure for the $\alpha$ N and $\beta$ C domains of clusterin. ....	152
Table 5.10:	Summary of bisANS fluorescence results for the $\alpha$ N and $\beta$ C domains of clusterin .....	155
Table 5.11:	Estimated kinetic constants for the binding of $\alpha$ N and $\beta$ C clusterin domains to LRP. ....	160
Table 5.12:	Analysis of the binding of the $\alpha$ N and $\beta$ C domains of clusterin to native protein ligands in ELISA .....	162

---

## List of Figures

Figure 1.1:	The protein trinity proposal for protein function.....	3
Figure 1.2:	Protein quality control systems operating within the cell.....	5
Figure 1.3:	Pathways of protein unfolding within a cell. ....	11
Figure 1.4:	Electron micrograph images of insulin amyloid fibrils. ....	14
Figure 1.5:	Predicted and known features of clusterin. ....	20
Figure 1.6:	Members of the low-density lipoprotein receptor superfamily. ....	26
Figure 1.7:	Schematic diagram of receptor-mediated endocytosis. ....	28
Figure 1.8:	Clusterin amino acid sequence showing the signal and a match to a critical binding motif in small heat shock proteins. ....	31
Figure 3.1:	Gateway cloning strategy. ....	50
Figure 3.2:	Schematic representation of clusterin showing the main predicted structural features of the protein and the mutation sites used in this study.....	60
Figure 3.3:	Entry clone plasmids linearised using Bgl II and separated based on size using a 0.85% agarose gel. ....	61
Figure 3.4:	Destination plasmids restricted with Sma I and separated using a 0.85% agarose gel.....	63
Figure 3.5:	Sequence alignment of translated sequences following DNA sequencing of destination plasmids constructed for the expression of clusterin substitution mutants.....	65
Figure 3.6:	Sequence alignment of translated sequences following DNA sequencing of destination plasmids constructed for the expression of clusterin truncation mutants. ....	67
Figure 3.7:	Dot blot confirming expression of mutant clusterin in supernatant from primary cultures of CHO cell transfectants. ....	69
Figure 3.8:	Immunoblots showing interaction between mutant clusterin proteins and three separate clusterin monoclonal antibodies.....	71
Figure 3.9:	Immunoblots indicating decrease in mutant protein expression after subsequent passages.....	72
Figure 3.10:	Immunoblots comparing reactivity strength of protein in supernatant between primary clones and secondary clones. ....	73
Figure 3.11:	Immunoblot testing for secretion of mutant T17 clusterin lacking the signal peptide.....	74
Figure 3.12:	Purification of wild type clusterin expressed in CHO cells using a 41D conjugated immunoaffinity column.....	75
Figure 3.13:	Composite showing coomassie stained 12% SDS-PAGE gels and Western blot comparing purified serum clusterin to CHO expressed clusterin. ....	76
Figure 3.14:	Coomassie stained 12% SDS-PAGE showing purified reduced CHO expressed clusterin from the rolling miniPERM culture compared to static culture. ....	78
Figure 3.15:	Size exclusion chromatography comparing the effect of rolling miniPERM vs static cultures on the expression of clusterin in CHO cells. ...	79
Figure 3.16:	Size exclusion chromatography comparing the expression of clusterin and mutant clusterin in CHO cells supplemented with different media.....	80

---

Figure 3.17:	SDS-PAGE and corresponding Western Blots of representative mutants, HT7 and serum clusterin.....	82
Figure 3.18:	Immunoblots comparing mutant protein interaction with the 41D antibody under native, denatured and reduced conditions. ....	83
Figure 3.19:	Size exclusion chromatography of serum clusterin and mutant clusterin at pH 5.5 and pH 7.4. ....	85
Figure 4.1:	Coomassie blue stained SDS-PAGE gel composite showing WT and DG clusterin. ....	101
Figure 4.2:	Mass spectrometry analysis of DG clusterin. ....	102
Figure 4.3:	Far-UV CD spectra for WT and DG clusterin at pH 6.0 and pH 7.5. ....	104
Figure 4.4:	BisANS fluorescence of WT and DG clusterin at pH 6.0 and pH 7.5. ....	105
Figure 4.5:	Size exclusion chromatography of WT and DG clusterin at both pH 7.5 and pH 6.0.....	107
Figure 4.6:	ELISA results showing the binding of WT and DG clusterin to native ligands at pH 7.5 and pH 6.0. ....	109
Figure 4.7:	ELISA results showing the binding of WT and DG clusterin to stressed proteins at pH 7.5 and pH 6.0. ....	110
Figure 4.8:	Surface plasmon resonance analysis of WT and DG clusterin binding to megalin.....	112
Figure 4.9:	Chaperone activity of WT and DG clusterin.....	114
Figure 4.10:	Flow cytometry histograms of fluorescence representing the binding of WT and DG clusterin to HepG2 cells. ....	115
Figure 5.1:	Schematic representation of the predicted structural features of clusterin showing the positions of the four domains to be expressed.....	126
Figure 5.2:	Graphical representation of the level of order overlaid with the level of hydrophobicity for each of four separate clusterin domains ....	142
Figure 5.3:	Agarose gel showing PCR products obtained following amplification of DNA encoding four domains of clusterin.....	143
Figure 5.4:	Agarose gel showing PCR products used to assess correct cloning of DNA encoding the $\alpha$ N domain into pET101. ....	145
Figure 5.5:	Sequences obtained following the confirmatory sequencing of plasmid constructs containing inserts clusterin domains.....	147
Figure 5.6:	Coomassie blue stained 18% SDS-PAGE gel and corresponding Western blot showing fractions produced during purification of the six-histidine tagged $\alpha$ N domain of clusterin. ....	151
Figure 5.7:	Far-UV CD spectra for the $\alpha$ N and $\beta$ C clusterin domains at pH 6.0, 7.0 and 8.0. ....	153
Figure 5.8:	Far-UV CD spectra for the $\alpha$ N and $\beta$ C clusterin domains at pH 6.0, 7.0 and 8.0 in the presence of 50% TFE. ....	154
Figure 5.9:	BisANS fluorescence for the $\alpha$ N and $\beta$ C domains of clusterin at pH 6.0, pH 7.0 and pH 8.0 ....	156
Figure 5.10:	Heat stability of the $\alpha$ N and the $\beta$ C domains of clusterin. ....	158
Figure 5.11:	Chaperone activities of the $\alpha$ N and $\beta$ C domains of clusterin. ....	159
Figure 5.12:	Surface plasmon resonance analysis of $\alpha$ N and $\beta$ C clusterin domains binding to LRP.....	161
Figure 5.13:	ELISA results showing the binding of the $\alpha$ N and $\beta$ C domains of clusterin to IgG at pH 6.0, pH 7.0 and pH 8.0 ....	163

---

Figure 5.14: ELISA results showing the binding of the $\alpha$ N and $\beta$ C domains of clusterin to heat-stressed lysozyme at pH 6.0, pH 7.0 and pH 8.0.....	164
Figure 5.15: ELISA results showing interaction between the $\alpha$ N and $\beta$ C domains of clusterin .....	165
Figure 6.1: Proposed fate of non-native proteins in the extracellular space.....	175

---

## Abbreviations

AD	Alzheimer's disease
AFU	arbitrary fluorescence units
Apo E	apolipoprotein E
Ap <sup>r</sup>	ampicillin resistance
ATP	adenosine triphosphate
A $\beta$ protein	amyloid beta protein
BCA	bicinchoninic acid
bisANS	5, 5'-bis(8-anilino-1-naphthalenesulfonate)
BSA	bovine serum albumin
CD	circular dichroism
CHO	Chinese hamster ovary
CL	clusterin
CO <sub>2</sub>	carbon dioxide
CS	citrate synthase
CSF	cerebrospinal fluid
DAB	diaminobenzidine
DG	deglycosylated
dH <sub>2</sub> O	distilled water
DMEM: F-12	Dulbecco's modified Eagles medium: Hams F-12
DMSO	dimethylsulfoxide
DNA	deoxyribonucleic acid
DTT	dithiothreitol
<i>E. coli</i>	<i>Escherichia coli</i>
ECL	enhanced chemiluminescence
EDTA	ethylene diamine tetraacetic acid
EGTA	ethylene glycol tetraacetic acid
ELISA	enzyme linked immunosorbent assay
ER	endoplasmic reticulum
ERAD	ER associated degradation
FCS	foetal calf serum
FITC	fluorescein isothiocyanate
<i>g</i>	relative centrifugal force 9.8 m.s <sup>-2</sup>
GST	glutathione S transferase
HBS	Hank's buffered saline
HDC	heat denatured casein
HMW	high molecular weight
HRP	horseradish peroxidase
IAA	iodoacetic acid

---

K <sub>d</sub>	dissociation constant
K <sub>m</sub> <sup>f</sup>	kanamycin resistance
LB	Luria-Bertani
LDL	low density lipoprotein
LDLR	low density lipoprotein receptor
LMW	low molecular weight
MRE	mean residue ellipticity
mRNA	messenger ribonucleic acid
MS	mass spectrometry
MTOC	microtubule organising centre
NFT	neurofibrillary tangle
PBS	phosphate buffered saline
PCD	protein conformational disorder
PCR	polymerase chain reaction
PD	Parkinson's disease
PF	protein free
PI	propidium iodide
ROS	reactive oxygen species
rpm	revolutions per minute
SAP	serum amyloid P component
SDS-PAGE	sodium dodecyl sulfate-polyacrylamide gel electrophoresis
SE	standard error
SEC	size exclusion chromatography
sHSP	small heat shock protein
SPR	surface plasmon resonance
TAE	tris acetate EDTA
TE	tris EDTA
TFE	trifluoroethanol
TTR	transthyretin
U	units
UV	ultraviolet
v/v	volume per volume
w/v	weight per volume
WT	wild type
βMe	beta mercaptoethanol

---

## Publications and Conference Presentations

### Publications

Stewart, E.M., Aquilina, A., Easterbrook-Smith, S.B., Murphy-Durland, D., Jacobsen, C., Moestrup, S., Wilson, M.R., (2007). Effects of Glycosylation on the Structure and Function of the Extracellular Chaperone Clusterin. *Biochemistry*. 46(5):1412-22.

Kumita, J.R., Poon, S., Caddy, G.L., Hagan, C.L., Dumoulin, M., Yerbury, J.J., Stewart, E.M., Robinson, C.V., Wilson, M.R., Dobson, C.M., (2007). The Extracellular Chaperone Clusterin Potently Inhibits Human Lysozyme Amyloid Formation by Interacting with Prefibrillar Species. *Journal of Molecular Biology*. 369(1):157-67.

Yerbury, J.J., Stewart, E.M., Wyatt, A.R., Wilson, M.R., (2005). Quality Control of Protein Folding in Extracellular Space. *EMBO Reports*. 6(12):1131-6.

### Conference Presentations

Stewart, E.M., Wyatt, A.R., Wilson, M.R. Probing the Structure of Clusterin and its Interaction with Megalin. *4<sup>th</sup> Workshop on Clusterin/ApoJ 2005*, Villars-sur-Ollon, Switzerland (Oral Presentation).

Stewart, E.M., Poon, S., Vine, K.L., Yerbury, J.J., Jones, R.A., Wilson, M.R. The Human Extracellular Chaperone Clusterin: How Does it Work? *29<sup>th</sup> Annual Lorne Conference on Protein Structure and Function 2004*, Lorne, Australia (Poster Presentation).

Stewart, E.M., Poon, S., Vine, K.L., Yerbury, J.J., Jones, R.A., Wilson, M.R. The Human Extracellular Chaperone Clusterin: How Does it Work?. *ComBio 2003*, Melbourne, Australia (Poster Presentation).

Yerbury, J.J., Stewart, E.M., Wyatt, A.R. Understanding Alzheimer's Disease: Protein Quality Control in the Extracellular Space. *Higher Degree Research Student Conference 2005*, Wollongong, Australia (Poster Presentation).

---

## **Abstract**

The incidence of protein conformational disorders is a problem affecting the aging population and is an increasing cost on the health system. These diseases involve the breakdown of control mechanisms within and outside of cells leading to accumulation of unfolded and misfolded proteins. The control of protein folding, both inside and outside the cell, is important to maintain the integrity of all proteins. Dysfunctions in this control may lead to the development of protein conformational disorders.

Intracellularly the mechanisms monitoring the correct translation, modification, assembly and transport of synthesised proteins are very well studied. However, in the harsh extracellular environment, mechanisms to control protein folding need further investigation. Extracellular chaperones have recently been proposed as an important part of extracellular quality control for protein folding.

The ubiquitous glycoprotein clusterin has been implicated in this extracellular quality control mechanism. A primary aim of the work described in this thesis was to examine the relationship between clusterin structure and function. This was done using three different approaches; characterisation of mutant clusterin expressed in transfected CHO cells; characterisation of enzymatically deglycosylated clusterin; and characterisation of bacterially expressed recombinant clusterin domains.

Initially a panel of mutants was designed to disrupt predicted features of the protein, consisting of five point mutants and five truncation mutants. The clusterin molecules were expressed in CHO cells and were proteolytically processed with two subunits and appeared to be normally glycosylated. The mutant clusterin molecules appeared to be chaperone-active to some degree also, evidenced by their copurification with non-



---

specific media proteins. In a rolling culture proteins in the media would be exposed to shear stress and one of the actions of clusterin is to bind to exposed hydrophobicity on stressed proteins. A decrease in the amount of contaminating proteins copurified with clusterin when static cultures were used instead of rolling cultures supports this argument.

In an effort to understand the importance of the glycosylation of clusterin, the conjugated sugars were enzymatically removed to determine their effects on clusterin function. The success of the deglycosylation process was first verified using SDS-PAGE and mass spectrometry. Structural features of the deglycosylated molecule were tested, with no change seen in the secondary structure of the deglycosylated protein compared to the native protein. A shift to slightly acidic pH produced no change in secondary structure as assessed by circular dichroism spectroscopy. Exposed hydrophobicity was seen to increase with the removal of the sugars but the  $K_d$  of the interaction with bisANS was not significantly different. At slightly acidic pH both the wild type and deglycosylated molecules exposed a greater amount of hydrophobicity to solution.

Binding to the known clusterin ligand megalin was also tested with a similar binding affinity seen for both molecules, however the removal of sugars increased the rate at which the molecule bound to and dissociated from megalin. Binding of the deglycosylated molecule to known native ligands (IgG and GST) and stressed protein ligands (lysozyme and BSA) was not affected by the absence of sugar moieties. The chaperone activity of the deglycosylated molecule was also not different to the wild type molecule.

Following the determination that the sugars appeared to have little effect on the activity of clusterin, a series of domains was cloned into bacterial expression vectors. Two

---

domains ( $\alpha$ N: D23-E112 and  $\beta$ C: R306-E449) were purified and their structure and function was examined. In the presence of a polar solvent both domains exhibited alpha helical secondary structure as expected based on amino acid analysis, though in aqueous buffer the domains had very little or no significant structure. The domains alone did not have any effect on the heat stressed precipitation of citrate synthase. Neither domain alone bound to heat-stressed lysozyme, however the  $\alpha$ N domain bound to the native protein ligand IgG and this was enhanced at slightly acidic pH, as seen with native clusterin. The  $\alpha$ N domain also bound with high affinity to LRP indicating that this domain of clusterin is likely to be involved in binding interactions of the entire molecule. Interaction between the  $\alpha$ N and  $\beta$ C domains was also observed and further investigation is required to determine binding and chaperone activity of the interacting domains.

Understanding the functional relationship between the structure and function of clusterin is important in understanding the role of clusterin in protein folding control. This knowledge may also be important in the development of novel treatments for the prevention or slowing of protein conformational diseases. The work in this manuscript showed that the deglycosylated form of clusterin is as potent a chaperone as the entire clusterin molecule. This indicated that a bacterially expressed form of clusterin may be used to further investigate the function of the molecule. Recombinant domains of clusterin were also studied to localise the regions of the molecule important in clusterin binding and chaperone function. Further investigation is needed, however the use of bacterially expressed recombinant proteins allows the potential development of recombinant chaperone-active clusterin which may ultimately be used as a therapeutic for protein conformational diseases. This research has gone some way to showing the best methods of characterising the structural relevance to the binding and chaperone activity of clusterin, and to providing a knowledge base for future investigations.